Calliditas Therapeutics ROA 2024

Calliditas Therapeutics Aktienanalyse

What does Calliditas Therapeutics do?

Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden. The company's goal is to develop innovative therapies for rare diseases and treat patients worldwide. The company is divided into two main business areas: clinical development and commercial products. The clinical development area focuses on identifying, developing, and marketing drugs for the treatment of kidney and liver diseases, as well as autoimmune diseases. The commercial products area distributes the developed medications. Calliditas' business model is based on the discovery and exploration of therapies for rare diseases. The company divides its pipeline into different product categories such as kidney and liver diseases, as well as autoimmune diseases. It is expected that this pipeline will make further progress over time and bring several products to market. Currently, Calliditas is in Phase 3 of clinical trials for Nefecon, a medication for the treatment of IgA nephropathy. IgA nephropathy is a rare kidney disease in which immunoglobulin A deposits in the kidneys can cause inflammation and damage. Nefecon is being developed to reduce the production of IgA and thereby reduce inflammation in the kidneys. Calliditas is also in Phase 2 of clinical trials for Atimmune, a medication for the treatment of autoimmune diseases. Atimmune aims to modulate the immune system to treat autoimmune diseases naturally. In addition, Calliditas is currently working on another medication for the treatment of liver diseases called FT-4202. FT-4202 is intended to increase the production of hemoglobin and thereby alleviate the symptoms of sickle cell anemia. Calliditas has an experienced team of researchers, clinicians, and salespeople dedicated to the development of medications for rare diseases. The company collaborates closely with experts in the field of kidney and liver diseases, as well as autoimmune diseases, to improve the development and marketing of its products. The company has also formed partnerships with other companies and industry stakeholders to support its research and development efforts. For example, Calliditas has entered into an agreement with Everest Medicines Ltd., a Chinese biotech company specializing in rare diseases, to market and distribute Nefecon in China. Overall, Calliditas has a promising pipeline of medications for the treatment of rare diseases. The company is well positioned to succeed in the coming years and improve the lives of patients around the world. Calliditas Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Calliditas Therapeutics's Return on Assets (ROA)

Calliditas Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Calliditas Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Calliditas Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Calliditas Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Calliditas Therapeutics stock

What is the Return on Assets (ROA) of Calliditas Therapeutics this year?

The Return on Assets (ROA) of Calliditas Therapeutics is -0.25 undefined this year.

What was the ROA of Calliditas Therapeutics compared to the previous year?

The ROA of Calliditas Therapeutics has increased by 18.78% compared to the previous year.

What consequences do high ROA have for investors of Calliditas Therapeutics?

A high ROA is advantageous for investors of Calliditas Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Calliditas Therapeutics?

A low ROA can be unfavorable for investors of Calliditas Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Calliditas Therapeutics affect the company?

An increase in ROA of Calliditas Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Calliditas Therapeutics impact the company?

A reduction in the ROA of Calliditas Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Calliditas Therapeutics?

Some factors that can influence the ROA of Calliditas Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Calliditas Therapeutics important for investors?

The ROA of Calliditas Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Calliditas Therapeutics take to improve ROA?

To improve ROA, Calliditas Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Calliditas Therapeutics pay?

Over the past 12 months, Calliditas Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Calliditas Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of Calliditas Therapeutics?

The current dividend yield of Calliditas Therapeutics is .

When does Calliditas Therapeutics pay dividends?

Calliditas Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Calliditas Therapeutics?

Calliditas Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Calliditas Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Calliditas Therapeutics located?

Calliditas Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Calliditas Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Calliditas Therapeutics from 10/4/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Calliditas Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Calliditas Therapeutics in the year 2023?

In the year 2023, Calliditas Therapeutics distributed 0 SEK as dividends.

In which currency does Calliditas Therapeutics pay out the dividend?

The dividends of Calliditas Therapeutics are distributed in SEK.